Kozo Yoshimori

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

Medicine, Oncology, Pharmacology +13

A cross-population atlas of genetic associations for 220 human phenotypes

Saori Sakaue, Masahiro Kanai, Yosuke Tanigawa et al. · Nature Genetics · 2021 · 2.4K citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 636 citations · Full text

Medicine, Oncology, Pharmacology +12

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 554 citations

Medicine, Oncology, Pharmacology +15

Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores

Omer Weissbrod, Masahiro Kanai, Huwenbo Shi et al. · Nature Genetics · 2022 · 281 citations · Full text

Life Sciences, Bioinformatics, Genetics +14